

Hepatitis C elimination in Belgium


Presented by

Y. Horsmans MD, PhD

Cliniques Universitaires Saint-Luc

Brussels

Historical inputs used to generate epidemiological data



Historical Input	Estimate	Estimate Year	Source
Anti-HCV Prevalence	0.87%	1994	Beutels 1997
Age and Gender Distribution	Shown Above	2004	De Maeght 2008, WIV
Spontaneous Clearance Rate	80.0%	2009	Deltenre 2010
Percent Diagnosed (anti-HCV)	58%	2009	Deltenre 2010
Annual Newly Diagnosed	2,850	2010	Gerkens 2012
Annual Number Treated	710	2010	Gerkens 2012; IMS Health

- Beutels M, Van Damme P, Aelvoet W, et al. Prevalence of hepatitis A, B and C in the Flemish population. Eur J Epidemiol 1997; 13: 275-80.
- De Maeght S, Henrion J, Bourgeois N, de Galocsy C, Langlet P, Michielsen P, Reynaert H, Robaey G, Sprengers D, Orlent H, et al. A pilot observational survey of hepatitis C in Belgium. Acta Gastroenterol.Belg. 2008 Jan;71(1):4-8.
- HepC Report, WIV, Peillaboratoria 2010
- Deltenre P, Moreno C, Mathurin P, et al. Impact of current treatment practice and different scenarios improving screening, access to treatment and treatment efficacy on hcv-related mortality in Belgium : a mathematical modeling approach. XXIIth Belgian Week of Gastroenterology . 2010.
- Gerkens S, Martin N, Thiry N, Hulstaert F. [Hepatitis C: Screening and Prevention] HEPATITIS C: SCREENING EN PREVENTIE. Belgian Health Care Knowledge Center (KCE); 2012.

Country: Hepatitis C burden of disease

- Epidemiological data:
 - Relatively recent consensus with local experts in HCV and in epidemiology
 - Accurate? To be validated in the future





Acta gastro-enterologica

P Bruggman. J of Viral Hepatitis, 2014, 21, (Suppl. 1), 5–33

	Australia	Austria	Belgium
Country's population (000)	22 900	8300	10 100
Year	2012	2008	1994
HCV antibody positive (000)			
Total cases	308 (277–339)	38 (8–60)	88 (12–114)
Prevalence	1.3% (1.2–1.5%)	0.5% (0.1–0.7%)	0.9% (0.1–1.1%)
Year of estimate	2012	2008	1994
Viremic infections (000)			
Total viremic cases	230 (207–253)	28 (6–44)	70 (10–91)
Viremic prevalence	1.0% (0.9–1.1%)	0.3% (0.1–0.5%)	0.7% (0.1–0.9%)
Viremic rate (%)	75	74	80
Year of estimate	2012	2008	1994
Genotypes (%)			
1a	20	20	–
1b	17	52	50
1 Other	17	–	9
2	55	72	59
3	5	5	6
4	37	19	19
5	2	4	14
6	–	–	2
Other	2	–	–
Year of estimate	–	2012	1994, 2004
Diagnosed (viremic)			
Total cases	185 000	9700	22 900
Annual newly diagnosed	11 300	600	2900
Year of estimate	2010	2012	2010
Treated			
Annual number treated	3900	1100	710
Year of estimate	2011	2011	2011
Liver transplants			
Total liver transplants	194	128	299
HCV liver transplants	69	28	38
% due to HCV	36	22	13
Year of estimate	2011	2011	2011


Hepatitis C Epidemiology in Belgium



Treatment of chronic hepatitis C

Number of patients in need of treatment?

Number of patients treated: 710 (2014) and 900-1300 (2015):



Belgium: National hepatitis plan 2014-2019




- published and brought out by the Minister of Health on **14 May 2014**
- Developed through collaboration between government, hepatologists, HIV specialists, patient groups, Harm reduction groups , professional groups of gastro-enterologists
- Goals of the plan:
 - Reduce transmission, increase the number of HCV + persons aware of their diagnosis and enhance patients' care pathway and quality of life
- Short overview of the planned activities: low level of implementation:
 1. Prevention: NA
 2. Testing: NA
 3. **Linkage to care and Health care pathway: Implemented through the reimbursement criteria of new all new DAAs:**
 - **A10: development of an HCV expert network:** HCV working group meetings to plan the future of HepC care- Nov'14-April '15
 - **A12 liverbiopsy no more mandatory:** Liverbiopsy not mandatory, evaluation of fibrosis still needed, other tools
 - **A14 evaluation of fibrosis staging for all genotypes, adapted to goal:** liverbiopsy or combination of 2 non invasive tests: radiologic & blood test
 - **A15 one national contact point with all stakeholders incl Pharma:** E-Health? KCE?
 - **A17 hospital distribution:** Reimbursement request through eHealth only through specialists attached to 7 academic centers
 - **A18 accelerate acces to new treatment:** reimb approval instantly through eHealth
 4. Hep A and Hep B vaccination: Implemented since >10 years
 5. Scientific Research:????




Country: Health care system

- Describe the health care system in view of the hepatitis prevention and control



Process of drug reimbursement in Belgium



What does your country expect from the international organisations in the support of control and treatment of viral hepatitis?

- Coordination throughout Europe regarding prevention and education
- Participation to the development of a campaign to identify undiagnosed HCV+ patients
- Help to develop a model of prevention regarding the risk of reinfection

Belgium: Hurdles towards HCV elimination

- Identify undiagnosed HCV+ (50% of 70.000?)
 - 70% are the babyboomers born between 1951 and 1975 (Public Health model)
- Access to treatment
 - F0-F1-F2
- Control onward transmission:
 - Growth of epidemic mainly new cases of HCV+ in
 - Migrants ;
 - PWIDs (Persons Who Inject Drugs) including former IV or paraphernal drug use
 - MSM @ high risk of HCV transmission
-